Proprietary Pipeline

Advancing our proprietary pipeline

We develop therapeutic cancer vaccines (immunotherapies) and prophylactic vaccines targeting major infectious diseases. Our most advanced proprietary program is a vaccine targeting HER2-expressing cancers, starting with breast cancer, which has shown promising results in preclinical studies, and is now in a Phase I clinical trial.

In addition to our internal pipeline, ExpreS2ion collaborates with the Universities of Oxford and Copenhagen, along with other consortium partners, to develop vaccines against Nipah virus, influenza, and malaria.

Beyond these programs, we are actively exploring undisclosed vaccine targets with shorter development timelines and cost-efficient pathways to value creation.